ArticleEmerging microbes & infections2025
Seroprevalence of Nipah virus and related paramyxoviruses in native frugivorous bats, Luzon, Philippines.
Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surveillance for Asiatic filoviruses and zoonotic paramyxoviruses at a perceived wildlife-human interface.Emerging microbes & infections · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV) is a highly virulent zoonotic virus classified as a priority pathogen and biohazard. In 2014, an outbreak of NiV-like disease in the Province of Sultan Kudarat, Mindanao, Philippines resulted in a 53% case fatality rate. Here, we identified wildlife bat hosts of NiV by conducting monthly serological surveillance of flying foxes and other native frugivorous bat species across Luzon. We estimated 13.92% NiV seroprevalence in native flying foxes. We also detected NiV neutralizing activity in some flying fox sera and identified factors such as age and seasonality as drivers of high anti-NiV antibody levels. In contrast, less than 10% NiV seroprevalence was detected in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.